Investing.com··Jordan ChusslerHims Stock Faces Lawsuit Pressure Despite Analyst Optimism on Valuation
Hims stock down 75% due to Novo Nordisk lawsuit over semaglutide marketing, but analysts see 150% upside potential and record revenue coming.
NVOHIMSanalyst-ratingsGLP-1 drugs